Compass Therapeutics (CMPX) Total Liabilities (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Total Liabilities for 3 consecutive years, with $22.8 million as the latest value for Q4 2025.
- Quarterly Total Liabilities rose 50.28% to $22.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.8 million through Dec 2025, up 50.28% year-over-year, with the annual reading at $22.8 million for FY2025, 50.28% up from the prior year.
- Total Liabilities hit $22.8 million in Q4 2025 for Compass Therapeutics, up from $21.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $23.5 million in Q2 2025 to a low of $4.1 million in Q1 2024.
- Historically, Total Liabilities has averaged $14.2 million across 3 years, with a median of $11.8 million in 2023.
- Biggest five-year swings in Total Liabilities: crashed 67.88% in 2024 and later soared 418.67% in 2025.
- Year by year, Total Liabilities stood at $8.3 million in 2023, then skyrocketed by 81.96% to $15.2 million in 2024, then soared by 50.28% to $22.8 million in 2025.
- Business Quant data shows Total Liabilities for CMPX at $22.8 million in Q4 2025, $21.6 million in Q3 2025, and $23.5 million in Q2 2025.